Perpetual Ltd Sells 81,043 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Perpetual Ltd trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 12.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 594,388 shares of the specialty pharmaceutical company's stock after selling 81,043 shares during the period. Perpetual Ltd owned about 0.98% of Jazz Pharmaceuticals worth $73,199,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in JAZZ. EverSource Wealth Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares during the period. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after acquiring an additional 121 shares during the period. UMB Bank n.a. grew its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 129 shares during the period. Ellsworth Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock valued at $4,675,000 after acquiring an additional 149 shares during the period. Finally, Cooper Financial Group grew its position in shares of Jazz Pharmaceuticals by 3.7% during the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company's stock valued at $534,000 after acquiring an additional 156 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $0.25 on Tuesday, hitting $121.43. The stock had a trading volume of 538,623 shares, compared to its average volume of 486,035. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market capitalization of $7.34 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56. The firm has a 50-day moving average of $122.66 and a 200-day moving average of $114.87.

Insider Activity

In other news, EVP Neena M. Patil sold 3,700 shares of the firm's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,253 shares of company stock worth $1,001,434. 4.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research reports. Morgan Stanley raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada reissued an "outperform" rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler reissued an "overweight" rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Finally, TD Cowen dropped their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $177.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.